Status:
UNKNOWN
Outcomes of Endoscopically Resected High-risk Mucosal and Low- and High-risk Submucosal Adenocarcinoma Arising in Barrett's Esophagus
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Conditions:
Barrett Esophagus
Adenocarcinoma Esophagus
Eligibility:
All Genders
Brief Summary
The purpose of this study is to assess lymph node metastasis rate, distant metastasis rate, disease-specific mortality, and overall mortality in patients with Barrett's related T1b and high risk T1a e...
Detailed Description
The incidence of esophageal adenocarcinoma (EAC) has increased six-fold over the last three decades, making it the most rapidly rising cancer in the Western world. The main histologic risk factor for ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Males or females, all ages
- Endoscopic resection of a histologically proven high risk T1a, low risk T1b EAC, or high risk T1b EAC
- Between 1/1/2008 and 1/1/2019
- Endoscopic resection and endoscopic FU (or other treatment after ER) have taken place in the participating center
- No written or oral refusal to use subject's data
- Exclusion Criterium:
- Objection against participation in this study
Exclusion
Key Trial Info
Start Date :
February 10 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT04818476
Start Date
February 10 2020
End Date
December 31 2022
Last Update
March 26 2021
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
Westmead hospital
Sydney, Australia
2
UZ Gasthuisberg
Leuven, Belgium
3
CHU Nantes
Nantes, France
4
Universitätsklinikum Augsburg
Augsburg, Germany